Endurant Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Endurant Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,273	Closed	-$194K	–	62
2022 Q2	$194K	Sell	5,273 -24	-0.5%	-$2.56K	0.07%	49
2022 Q1	$811K	Sell	5,297 -674	-11%	-$138K	0.21%	59
2021 Q4	$1.76M	Sell	5,971 -4,269	-42%	-$1.25M	0.43%	44
2021 Q3	$2.84M	Sell	10,240 -3,064	-23%	-$831K	0.65%	35
2021 Q2	$3.65M	Buy	+13,304	New	+$4.76M	1%	37

Other funds holding PRAX

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Endurant Capital Management's PRAX Position: Q3 2022 in Review

Endurant Capital Management sold out of Praxis Precision Medicines (PRAX) in Q3 2022, closing a stake of 5,273 shares — an estimated $194K sold.

Endurant Capital Management first reported a position in PRAX in Q2 2021 and held it in 5 quarters. The position peaked at $3.65M in Q2 2021. 108 funds tracked by Wall St. Rank hold PRAX as of Q3 2022.

Endurant Capital Management reported no remaining Praxis Precision Medicines position as of Q3 2022 after selling out during the quarter.
Endurant Capital Management sold 5,273 Praxis Precision Medicines shares in Q3 2022, an estimated $194K.
Endurant Capital Management first reported a position in Praxis Precision Medicines in Q2 2021 and held it in 5 quarters.
Endurant Capital Management's Praxis Precision Medicines position peaked at $3.65M in Q2 2021.
108 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2022.

Based on Endurant Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.